Sun Pharma plans capex for R&DIllustrative image – not actual.

Sun Pharma intends to invest on research and development (R&D) during the FY12.

The company has earmarked Rs 450 crore for the purpose. The capex plan will be for Sun, its United States subsidiary Caraco Pharmaceutical Laboratories and Israeli drug-maker Taro, which was acquired in September 2010.

Meanwhile, the company is keen on acquisition opportunities in the US and is scouting for the same.

← All latest storiesBack to top →